Aubrey Capital Management’s Pacira BioSciences PCRX Stock Holding History

Aubrey Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,651	Closed	-$231K	–	53
2023 Q1	$231K	Hold	5,651	–	–	0.13%	45
2022 Q4	$218K	Hold	5,651	–	–	0.17%	42
2022 Q3	$301K	Hold	5,651	–	–	0.26%	37
2022 Q2	$329K	Sell	5,651 -1,245	-18%	-$81.6K	0.27%	40
2022 Q1	$526K	Buy	6,896 +600	+10%	+$40K	0.3%	38
2021 Q4	$379K	Hold	6,296	–	–	0.15%	29
2021 Q3	$353K	Hold	6,296	–	–	0.11%	33
2021 Q2	$382K	Hold	6,296	–	–	0.11%	33
2021 Q1	$441K	Hold	6,296	–	–	0.12%	37
2020 Q4	$377K	Buy	+6,296	New	+$369K	0.09%	37

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Aubrey Capital Management's PCRX Position: Q2 2023 in Review

Aubrey Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2023, closing a stake of 5,651 shares — an estimated $231K sold.

Aubrey Capital Management first reported a position in PCRX in Q4 2020 and held it in 10 quarters. The position peaked at $526K in Q1 2022. 258 funds tracked by Wall St. Rank hold PCRX as of Q2 2023.

Aubrey Capital Management reported no remaining Pacira BioSciences position as of Q2 2023 after selling out during the quarter.
Aubrey Capital Management sold 5,651 Pacira BioSciences shares in Q2 2023, an estimated $231K.
Aubrey Capital Management first reported a position in Pacira BioSciences in Q4 2020 and held it in 10 quarters.
Aubrey Capital Management's Pacira BioSciences position peaked at $526K in Q1 2022.
258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2023.

Based on Aubrey Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.